CMS: Aduhelm Coverage Determination Doesn’t Take Into Account Cost

By Dorothy Mills-Gregg / January 11, 2022 at 7:37 PM
CMS did not consider Aduhelm’s price tag, recently lowered to $28,000, when deciding whether Medicare should cover the controversial Alzheimer’s drug, CMS Office of Communications Director Beth Lynk told reporters Tuesday (Jan. 11) after the agency announced it would cover Biogen’s drug in certain situations . CMS announced in November that 2022 Medicare Part B premiums would jump $21.60 this year in part to build up the Part B Medicare trust fund in case CMS covered Aduhelm. Lawmakers and advocates...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.